T-Cell Lymphomas Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030

| About GlobalData

1 T-Cell Lymphomas: Executive Summary

1.1 The T-Cell Lymphoma Market Will Grow to $1.77B by 2030, at a

6.4% CAGR

1.2 New Target Development and Creating Niche Sub-Markets Within CTCL or PTCL Are Dominant R&D Strategies

1.3 A High Level of Unmet Need Will Remain for Most TCL Subtypes During the Forecast Period

1.4 The Late-Stage Pipeline in T-Cell Lymphoma Is Rich, Albeit Unlikely to Provide Clinical Benefit of a Large Magnitude

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 Forecast Methodology

4.4.1 Sources

4.4.2 Forecast Assumptions and Methods

4.5 Epidemiological Forecast for T-Cell Lymphomas

4.5.1 Diagnosed Incident Cases of TCL

4.5.2 Age-Specific Diagnosed Incident Cases of TCL

4.5.3 Sex-Specific Diagnosed Incident Cases of TCL

4.5.4 Diagnosed Incident Cases of TCL by Subtype

4.5.5 Diagnosed Incident Cases of TCL by Stage at Diagnosis

4.5.6 Diagnosed Incident Cases of TCL by CD30 Expression

4.5.7 Five-Year Diagnosed Prevalent Cases of TCL

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 COVID-19 Impact

4.6.3 Limitations of the Analysis

4.6.4 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 KOL Insights on Disease Management

5.2.1 Diagnosis

5.2.2 Early-Stage Treatment

5.2.3 Systemic Therapy

5.2.4 Transplant

5.2.5 Relapsed/Refractory

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Better Systemic Treatments for CTCL

7.3 Primarily Refractory and Relapsed PTCL Patients

7.4 Combinational Approaches in Clinical Trials

7.5 Maintenance Regimens for PTCL Patients in Remission

7.6 Clinical Trials for Biomarker-Driven Agents to Capitalize on Validated Targets

8 R&D Strategies

8.1 Overview

8.1.1 Serving Underserved Markets with Proven Mechanisms of Action

8.1.2 Subtype-Specific Drug Launches

8.1.3 Focus on Novel Targets

8.2 Clinical Trials Design

8.2.1 Rarity of the Disease

8.2.2 More Flexible Inclusion/Exclusion Criteria in Clinical Trials Are Required

8.2.3 Primary and Secondary Endpoints

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers – Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key Events

12.3.3 Drivers and Barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key Events

12.4.3 Drivers and Barriers

12.5 China

12.5.1 Forecast

12.5.2 Key Events

12.5.3 Drivers and Barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Managing Epidemiologist

13.6.5 Vice President of Disease Analysis and Intelligence

13.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table 1: T-Cell Lymphomas: Key Metrics in the 8MM

Table 2: Subtype Classification and Staging Systems Used for T-Cell Lymphomas

Table 3: Risk Factors and Comorbidities for TCL

Table 4: Treatment Guidelines for T-Cell Lymphomas

Table 5: Key Pivotal T-Cell Lymphoma Clinical Trials with Their Clinical Outcomes

Table 6: Top 10 Deals by Value, 2016–21

Table 7: T-Cell Lymphomas Market – Global Drivers and Barriers, 2020–30

Table 8: Key Events Impacting Sales for T-Cell Lymphomas in the US, 2020–30

Table 9: T-Cell Lymphomas Market – Drivers and Barriers in the US, 2020–30

Table 10: Key Events Impacting Sales for T-Cell Lymphomas in the 5EU, 2020–30

Table 11: T-Cell Lymphomas Market – Drivers and Barriers in the 5EU, 2020–30

Table 12: Key Events Impacting Sales for T-Cell Lymphomas in Japan, 2020–30

Table 13: T-Cell Lymphomas Market – Drivers and Barriers in Japan, 2020–30

Table 14: Key Events Impacting Sales for T-Cell Lymphomas in China, 2020–30

Table 15: T-Cell Lymphomas Market – Drivers and Barriers in China, 2020–30

Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for T-Cell Lymphomas in 2020 and 2030

Figure 2: Analysis of the Company Portfolio Gap in T-Cell Lymphomas During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Biologic Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of T-Cell Lymphomas During the Forecast Period

Figure 4: Competitive Assessment of the Late-Stage Small Molecule Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of T-Cell Lymphomas During the Forecast Period

Figure 5: Key Therapeutic Targets in TCL

Figure 6: 8MM, Diagnosed Incidence of TCL, Men and Women, Cases per 100,000 Population, All Ages, 2010 and 2020

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of TCL

Figure 8: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of TCL by Subtype

Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of TCL By Stage at Diagnosis

Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of TCL by CD30 Expression

Figure 11: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of TCL

Figure 12: 8MM, Diagnosed Incident Cases of TCL, N, Both Sexes, All Ages, 2020

Figure 13: 8MM, Diagnosed Incident Cases of TCL by Age, N, Both Sexes, 2020

Figure 14: 8MM, Diagnosed Incident Cases of TCL by Sex, N, All Ages, 2020

Figure 15: 8MM, Diagnosed Incident Cases Proportion of TCL (CTCL and PTCL) by Subtype, %, Both Sexes, All Ages, 2020

Figure 16: 8MM, Diagnosed Incident Cases Proportions of MF and SS by Stage at Diagnosis, %, Both Sexes, All Ages, 2020

Figure 17: 8MM, Diagnosed Incident Cases Proportion of Primary Cutaneous ALCL and Others by Stage at Diagnosis, %, Both Sexes, All Ages, 2020

Figure 18: 8MM, Diagnosed Incident Cases Proportion of PTCL by Stage at Diagnosis, %, Both Sexes, All Ages, 2020

Figure 19: 8MM, Diagnosed Incident Cases Proportion of TCL with CD30 Expression, %, Both Sexes, All Ages, 2020

Figure 20: 8MM, Five-Year Diagnosed Prevalent Cases of TCL, N, Both Sexes, All Ages, 2020

Figure 21: Treatment Algorithm in Cutaneous TCL

Figure 22: Treatment Algorithm in Peripheral TCL

Figure 23: Unmet Needs and Opportunities in T-Cell Lymphomas

Figure 24: Overview of the Development Pipeline in T-Cell Lymphomas

Figure 25: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for T-Cell Lymphomas in the 8MM During the Forecast Period

Figure 26: Competitive Assessment of the Marketed and Pipeline Small Molecule Inhibitors and Chemotherapies Benchmarked Against the Standard of Care, HDAC inhibitors (i.e., Istodax)

Figure 27: Competitive Assessment of the Marketed and Pipeline Targeted Monoclonal Antibodies and Immune Checkpoint Inhibitors Benchmarked Against the Standard of Care, Adcetris

Figure 28: Analysis of the Company Portfolio Gap in T-Cell Lymphomas During the Forecast Period

Figure 29: Global (8MM) Sales Forecast by Country for T-Cell Lymphomas in 2020 and 2030

Figure 30: Sales Forecast by Class for T-Cell Lymphomas in the US in 2020 and 2030

Figure 31: Sales Forecast by Class for T-Cell Lymphomas in the 5EU in 2020 and 2030

Figure 32: Sales Forecast by Class for T-Cell Lymphomas in Japan in 2020 and 2030

Figure 33: Sales Forecast by Class for T-Cell Lymphomas in China in 2020 and 2030